Skip to content

Released May 9, 2016, after the close

10-Q filed May 9, 2016, 39 days after period end · 0001564590-16-018578

Q1 2016 · 10-Q
Revenue$1.32Mno prior Q1 2015 on file+22.9% vs Q4 2015
Net Income-$8.38MN/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.29N/M vs Q1 2015N/M vs Q4 2015
Operating Income-$7,916,000N/M
Operating Cash Flow-$7,252,000N/M
Free Cash Flowderived-$7,430,000N/M
Margins · derived
Operating margin-598.8%
Net margin-633.7%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2016Q1 2015Q1 2014Q1 2013
Revenue$1.32M——$472.00K
Net Income-$8.38M-$7.88M-$6.98M-$3.55M
EPS Diluted-$0.29-$0.38-$0.34-$2.92

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR